Tubiana-Rufi N, Munz-Licha G
Service d'endocrinologie et de diabétologie, Hôpital Robert Debré, Paris.
Diabetes Metab. 1997 Sep;23 Suppl 3:58-62.
Quality of life was assessed in a multicentre random cross-over study (UK-Benelux) of 189 well-controlled IDDM patients undergoing treatment with lispro insulin analog (Lilly). Lispro offered several advantages over regular insulin for intensive diabetes treatment. Patients were more satisfied, felt more flexible in their lifestyle (no delayed meals due to injections, need for fewer snacks), reported a decrease in hypoglycaemic episodes, and considered their glycaemic control as better during the lispro period. Seventy-four percent of patients elected to continue treatment with lispro. A study of different injection times related to meals provided better knowledge of postprandial blood glucose excursions after lispro and showed that the optimal time for lispro injection was just before the meal, which was very convenient for the patients. Another study showed that lispro analogue, because of its pharmacokinetic properties, can reduce dietary restrictions in well-controlled IDDM patients on intensified insulin treatment.
在一项针对189名接受赖脯胰岛素类似物(礼来公司生产)治疗且病情控制良好的胰岛素依赖型糖尿病(IDDM)患者的多中心随机交叉研究(英国-比荷卢经济联盟)中,对生活质量进行了评估。与常规胰岛素相比,赖脯胰岛素在强化糖尿病治疗方面具有多个优势。患者更加满意,感觉生活方式更灵活(不会因注射而延迟用餐,所需零食更少),报告低血糖发作次数减少,并认为在使用赖脯胰岛素期间血糖控制更好。74%的患者选择继续使用赖脯胰岛素治疗。一项关于与进餐相关的不同注射时间的研究,使人们对赖脯胰岛素餐后血糖波动有了更好的了解,并表明赖脯胰岛素的最佳注射时间是进餐前,这对患者非常方便。另一项研究表明,由于其药代动力学特性,赖脯胰岛素类似物可减少接受强化胰岛素治疗且病情控制良好的IDDM患者的饮食限制。